Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: Differential effect on proliferating endothelial cells

British Journal of Cancer

Volumn 83, Issue 8, 2000, Pages 1077-1083

  Wild, R ^a   Dhanabal, M ^b   Olson, T A ^c   Ramakrishnan, S ^d  

^a SUGEN INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Angiogenesis; Diphtheria toxin; KDR flk 1; Neuropilin 1; Vascular endothelial growth factor; VEGF

Indexed keywords

DIPHTHERIA TOXIN; NEUROPILIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033778445     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1439     Document Type: Article

References (28)

1. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
2. Tumour vasculature-a potential therapeutic target
3. Eradication of large solid Tumours in mice with an immunotoxin directed against Tumour vasculature
4. Up-regulation of endoglin on vascular endothelial cells in human solid tumours: Implications for diagnosis and therapy
5. Endothelial cell proliferation as a novel approach to targeting tumour therapy
6. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumours and adenoviral vectors
7. The role of angiogenesis in tumour growth
8. Use of immunotoxin to inhibit proliferating human corneal endothelium
9. Development of antiangiogenin peptide using a phage-displayed peptide library
10. Selective binding of VEGF 121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells
11. Vessel cooption, regression, and growth in tumours mediated by angiopoietins and VEGF
12. Angiogenesis: A dynamic balance of stimulators and inhibitors
13. Delivery of molecular and cellular medicine to solid tumours
14. Tumour targeting through fibroblast growth factor receptors
15. A novel method to purify recombinant vascular endothelial growth factor (VEGF121) expressed in yeast
16. Expression and radiolabeling of recombinant proteins containing a phosphorylation motif
17. Vascular endothelial growth factor (VEGF) and its receptors
18. Targeting the tumour vasculature: Inhibition of tumour growth by a vascular endothelial growth factor-toxin conjugate
19. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of Tumour angiogenesis
20. Angiogenesis in malignant gliomas
21. Cytotoxic conjugates containing translational inhibitory proteins
22. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
23. Long-lasting complete inhibition of human solid tumours in SCID mice by targeting endothelial cells of tumour vasculature with antihuman endoglin immunotoxin
24. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumour cells that bind VEGF165 via its exon 7-encoded domain
25. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165
26. Neuropilin-1 is expressed by endothelial and tumour cells as an isoform-specific receptor for vascular endothelial growth factor
27. VEGFs, receptors and angiogenesis
28. Quantitative assessment of angiogenesis and tumour vessel architecture by computer assisted digital image analysis: Effects of VEGF-toxin conjugate on tumour microvessel density